|Podcasts|June 11, 2019
Episode 33: Translationally Enabled Pharma
Author(s)Lisa Henderson, Christen Harm
Pharm Exec editors speak with Jigar Raythatha, CEO of Constellation Pharmaceuticals. He talks about his roles, the importance of having a Plan B in biotech, creating a translationally enabled company, and how he leads his team at Constellation.
Advertisement
Pharm Exec editors speak with Jigar Raythatha, CEO of Constellation Pharmaceuticals. He talks about his roles, the importance of having a Plan B in biotech, creating a translationally enabled company, and how he leads his team at Constellation.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration
2
Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly
3
When Drug Pricing Becomes Trade Policy
4
Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb
5